Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-institution, phase Ib trial that evaluates the safety and
tolerability and preliminary anti-tumor activity of fulvestrant, palbociclib and erdafitinib
in patients with ER+/HER2-/FGFR-amplified metastatic breast cancer.